Compare CE & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CE | BLTE |
|---|---|---|
| Founded | 1918 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2004 | 2021 |
| Metric | CE | BLTE |
|---|---|---|
| Price | $45.50 | $171.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $64.29 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.4M | 175.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 23.62 | N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $9,544,000,000.00 | N/A |
| Revenue This Year | $3.14 | N/A |
| Revenue Next Year | $2.83 | $492.11 |
| P/E Ratio | $30.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.13 | $68.21 |
| 52 Week High | $70.70 | $200.00 |
| Indicator | CE | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 52.75 |
| Support Level | $43.78 | $167.80 |
| Resistance Level | $45.64 | $172.02 |
| Average True Range (ATR) | 1.66 | 8.15 |
| MACD | 0.15 | -0.63 |
| Stochastic Oscillator | 35.09 | 43.03 |
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.